GSK plc 6-K, filed Dec 17, 2021
GSK plc (GSK)
6-K
2021-12-17
For: 2021-12-17
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on December 17, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 17 December 2021, London UK and San Francisco,
US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc.
(Nasdaq: VIR) today announced that the European Commission (EC) has
granted marketing authorisation to Xevudy (sotrovimab) for the early treatment of
COVID-19. Sotrovimab is now approved in the European Union (EU) for
the treatment of adults and adolescents (aged 12 years and over and
weighing at least 40kg) with COVID-19 who do not require
supplemental oxygen and who are at increased risk of progressing to
severe COVID-19.
The grant of the marketing authorisation in the EU is a result of
the positive opinion issued on 16 December by the European
Medicines Agency's Committee for Human Medicinal Products
(CHMP).
In July 2021, GSK and Vir announced a Joint Procurement Agreement
(JPA) with the EC to supply up to 220,000 doses of sotrovimab.
Following the grant of the marketing authorisation in the EU,
Member States participating in the JPA can now order sotrovimab to
support their pandemic responses.
Dr Hal Barron, Chief Scientific Officer and President R&D, GSK,
said: "Since the start of
the pandemic we have seen an unprecedented effort by governments,
academia and industry to find solutions to help as many people as
quickly as possible. COVID-19 therapeutics are an important part of
the solution. We have already been working to lay the foundation
for more patients across Europe to access sotrovimab through the
Joint Procurement Agreement with the European Commission. With
today's marketing authorisation we are now able to expand access,
and we are discussing with governments how we can bring sotrovimab
to more patients."
George Scangos, PhD, chief executive officer of Vir,
said: "The grant of the
marketing authorisation in the European Union
for sotrovimab marks yet another important
milestone in our efforts to combat COVID-19, as it allows us to
expand access across multiple countries working to address this
challenge. Given recent pre-clinical data from our own labs, as
well as that of other independent labs, demonstrating that
sotrovimab retains activity against the rapidly spreading Omicron
variant and all other currently tested variants of concern and
interest, we remain confident in the critical role of sotrovimab
and look forward to further contributing to the fight against this
pandemic."
The grant of the marketing authorisation in the EU is based on data
from the COMET-ICE phase III
trial, demonstrating that
intravenous treatment with sotrovimab resulted in a 79% reduction
(adjusted relative risk reduction) (p<0.001) in all-cause
hospitalisations for more than 24 hours or death due to any cause
by Day 29 compared to placebo, meeting the primary endpoint of the
trial. In absolute numbers, 30 (6%) of the 529 patients in the
placebo arm progressed, compared to six (1%) of the 528 patients
receiving sotrovimab. In clinical trials conducted to date,
sotrovimab has been well-tolerated. The most common adverse
reactions are hypersensitivity and infusion-related reactions, seen
in approximately 2% and 1% of cases,
respectively.
GSK and Vir are committed to the ongoing evaluation of sotrovimab
as the COVID-19 landscape continues to evolve at different rates
across the globe and new variants of concern and interest emerge.
Updated in vitro data, published in bioRxiv,
demonstrate that sotrovimab retains activity against all tested
variants of concern and interest of the SARS-CoV-2 virus as defined
by the World Health Organization, including, but not limited to,
Omicron (B.1.1.529), Delta (B.1.617.2), Delta Plus (AY.1 or AY.2)
and Mu (B.1.621).
About Xevudy (sotrovimab)
Xevudy (sotrovimab)
is an investigational SARS-CoV-2 neutralising monoclonal antibody.
The antibody binds to an epitope on SARS-CoV-2 shared with
SARS-CoV-1 (the virus that causes SARS), indicating that the
epitope is highly conserved, which may make it more difficult for
resistance to develop. Sotrovimab, which incorporates Xencor,
Inc.'s Xtend™ technology, has also been designed to achieve
high concentration in the lungs to ensure optimal penetration into
airway tissues affected by SARS-CoV-2 and to have an extended
half-life.
About global access to sotrovimab
Sotrovimab is authorised for emergency use in the
US. Xevudy (sotrovimab) has been granted a Marketing
Authorisation in the EU, conditional marketing authorisation in
Great Britain, provisional marketing authorisation in Australia,
and conditional marketing authorisation in Saudi Arabia. It has
also been approved via Japan's Special Approval for Emergency
Pathway. Temporary authorisations for sotrovimab have been granted
in 12 other countries.
Sotrovimab is supplied in several countries worldwide, including
through national agreements in the US, UK, Japan, Australia,
Canada, Singapore, Switzerland, and the United Arab Emirates. The
companies have also announced a JPA with the EC to supply doses of
sotrovimab to participating Member States of the EU. Additional
agreements are yet to be disclosed due to confidentiality or
regulatory requirements.
Important information about sotrovimab in the European
Union
For more information on the marketing authorisation in the European
Union, please review the Summary of Product Characteristics (SmPC).
Healthcare professionals should look out for side effects and take
appropriate action.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of
the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions
via the national reporting system listed
in Appendix
V.
Warnings and precautions
Hypersensitivity reactions including anaphylaxis
Hypersensitivity reactions, including anaphylaxis, have been
reported with administration of sotrovimab (see section 4.8 of the
SmPC). If signs or symptoms of a clinically significant
hypersensitivity reaction or anaphylaxis occur, administration
should be discontinued immediately and appropriate medications
and/or supportive care should be given.
Infusion-related reactions
Infusion-related reactions (IRRs) have been observed with
intravenous administration of monoclonal antibodies (see section
4.8 of the SmPC). These reactions may be severe or
life-threatening. If an IRR occurs, the infusion may be
interrupted, slowed or stopped.
Adverse reactions
The most common adverse reactions were hypersensitivity reactions
(2%) and infusion-related reactions (1%). The most serious adverse
reaction was anaphylaxis (0.05%).
Pregnancy
There are no data from the use of sotrovimab in pregnant women.
Animal studies have not been evaluated with respect to reproductive
toxicity. In a cross-reactive binding assay using a protein array
enriched for human embryofoetal proteins, no off-target binding was
detected. Since sotrovimab is a human immunoglobulin G (IgG), it
has the potential for placental transfer from the mother to the
developing foetus. The potential treatment benefit or risk of
placental transfer of sotrovimab to the developing foetus is not
known. Sotrovimab should be used during pregnancy only if the
expected benefit to the mother justifies the potential risk to the
foetus.
Lactation
It is not known whether sotrovimab is excreted in human milk or
absorbed systemically after ingestion. Administration of sotrovimab
while breast-feeding can be considered when clinically
indicated.
Sotrovimab in the United States
The following is a summary of information for sotrovimab.
Healthcare providers in the US should review the Fact Sheets for
information about the authorized use of sotrovimab and mandatory
requirements of the Emergency Use Authorization (EUA). Sotrovimab
has been authorized by the US FDA for the emergency use described
below. Sotrovimab is not FDA-approved for this use.
Sotrovimab is authorized only for the duration of the declaration
that circumstances exist justifying the authorization of the
emergency use of sotrovimab under section 564(b)(1) of the Act, 21
U.S.C. § 360bbb-3(b)(1), unless the authorization is
terminated or revoked sooner.
Authorized Use
The US FDA has issued an EUA to permit the emergency use of the
unapproved product sotrovimab for the treatment of mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults and pediatric
patients (12 years of age and older weighing at least 40kg) with
positive results of direct SARS-CoV-2 viral testing, and who are at
high risk for progression to severe COVID-19, including
hospitalization or death.
Limitations of Authorized Use
Sotrovimab is not authorized for use in patients:
● who are hospitalized due to COVID-19,
OR
● who require oxygen therapy due to COVID-19,
OR
● who require an increase in baseline oxygen flow
rate due to COVID-19 (in those on chronic oxygen therapy due to
underlying non-COVID-19 related comorbidity)
Benefit of treatment with sotrovimab has not been observed in
patients hospitalized due to COVID19. SARS-CoV-2 monoclonal
antibodies may be associated with worse clinical outcomes when
administered to hospitalized patients with COVID19 requiring high
flow oxygen or mechanical ventilation.
Please see the Food and Drug
Administration (FDA) Letter of
Authorization,
full Fact Sheet for
Healthcare Providers and
full Fact Sheet for
Patients, Parents, and Caregivers.
About the GSK and Vir collaboration
In April 2020, GSK and Vir entered into a collaboration to research
and develop solutions for coronaviruses, including SARS-CoV-2, the
virus that causes COVID-19. The collaboration uses Vir's
proprietary monoclonal antibody platform technology to accelerate
existing and identify new anti-viral antibodies that could be used
as therapeutic or preventive options to help address the current
COVID-19 pandemic and future outbreaks. The companies will leverage
GSK's expertise in functional genomics and combine their
capabilities in CRISPR screening and artificial intelligence to
identify anti-coronavirus compounds that target cellular host
genes. They will also apply their combined expertise to research
SARS-CoV-2 and other coronavirus vaccines.
GSK commitment to tackling COVID-19
GSK's response to COVID-19 has been one of the broadest in the
industry, with potential treatments in addition to the Company's
vaccine candidates in development with partner
organisations.
GSK is collaborating with several organisations on COVID-19
vaccines by providing access to its adjuvant
technology. The Company is
working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd.
to develop adjuvanted, protein-based vaccine candidates, and all
are now in phase III clinical trials. The use of an adjuvant can be
of particular importance in a pandemic since it may reduce the
amount of vaccine protein required per dose, allowing more vaccine
doses to be produced and contributing to protecting more people in
need.
GSK is also working with mRNA specialist CureVac NV to
jointly develop next-generation, optimised mRNA vaccines for
COVID-19 with the potential to address multiple emerging variants
in one vaccine.
GSK is also exploring treatments for COVID-19 patients,
collaborating with Vir Biotechnology to investigate monoclonal
antibodies that could be used as therapeutic or preventive options
for COVID-19.
Vir's commitment to COVID-19
Vir was founded with the mission of addressing the world's most
serious infectious diseases. In 2020, Vir responded rapidly to the
COVID-19 pandemic by leveraging our unique scientific insights and
industry-leading antibody platform to explore multiple monoclonal
antibodies as potential therapeutic or preventive options for
COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir
advanced into the clinic. It was carefully selected for its
demonstrated promise in preclinical research, including an
anticipated high barrier to resistance and potential ability to
both block the virus from entering healthy cells and clear infected
cells. Vir is continuing to pursue novel therapeutic and
prophylactic solutions to combat SARS-CoV-2 and future
coronavirus pandemics, both independently and in collaboration with
its partners.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused
on combining immunologic insights with cutting-edge technologies to
treat and prevent serious infectious diseases. Vir has assembled
four technology platforms that are designed to stimulate and
enhance the immune system by exploiting critical observations of
natural immune processes. Its current development pipeline consists
of product candidates targeting COVID-19, hepatitis B virus,
influenza A and human immunodeficiency virus. For more information,
please visit www.vir.bio.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Vir Biotechnology Contacts:
Heather Rowe
Armstrong
Cara Miller
VP, Investor Relations
VP, Corporate Communications
harmstrong@vir.bio cmiller@vir.bio
+1 415 915
4228
+1 415 941 6746
GSK cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020, GSK's 2021 Q3 Results and any
impacts of the COVID-19 pandemic.
Vir forward-looking statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "will," "plan," "potential," "aim,"
"promising" and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
forward-looking statements are based on Vir's expectations and
assumptions as of the date of this press release. Forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the ability of sotrovimab to treat
and/or prevent COVID-19 either through IV or IM administration,
Vir's collaboration with GSK, plans to progress
regulatory submissions globally, including with the FDA regarding
the existing EUA for sotrovimab, planned discussions with other global regulatory
agencies, the timing of availability of clinical data, program
updates and data disclosures, the clinical development program for
sotrovimab, and the ability of sotrovimab to maintain activity
against circulating variants of concern and interest, including
Omicron. Many factors may cause differences between current
expectations and actual results, including unexpected safety or
efficacy data observed during preclinical or clinical studies,
challenges in the treatment of hospitalized patients, difficulties
in collaborating with other companies or government agencies,
challenges in accessing manufacturing capacity, successful
development and/or commercialization of alternative product
candidates by Vir's competitors, changes in expected or existing
competition, delays in or disruptions to Vir's business or clinical
trials due to the COVID-19 pandemic, geopolitical changes or other
external factors, and unexpected litigation or other disputes.
Other factors that may cause actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Vir's filings with the U.S.
Securities and Exchange Commission, including the section titled
"Risk Factors" contained therein. Except as required by law, Vir
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
17, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|